| Literature DB >> 30810094 |
Susana Ramalho1, Liliana Al De Angelo Andrade2, Cássio Cardoso Filho1, Rodrigo de Andrade Natal3, Marina Pavanello4, Amanda Canato Ferracini4, Luis Felipe Sallum1, Luis Otávio Sarian1, Sophie Derchain1.
Abstract
The objective of this study is to evaluate the relationship between discoidin domain receptor 2 (DDR2) and miR-182 expression with response to platinum-based chemotherapy and survival in women with high-grade serous ovarian cancer (HGSOC). We evaluated 78 women with HGSOC stages I-IV, diagnosed between 1996 and 2013, and followed up until 2016. DDR2 expression was assessed using immunohistochemistry on tissue microarray slides. The microRNAs were evaluated by qRT-PCR. DDR2 expression was high in 11 (14.1%) women. PFS was significantly lower in women with FIGO stage I/II - versus III/IV, post-surgery residual disease and high expression of DDR2. Women with postsurgery residual disease, FIGO stage I/II - versus III/IV and DDR2 expression had worse OS, but only post-surgery residual disease remained an independent prognostic factor for worse OS in multivariable analysis. miR-182 expression levels were significantly lower in patients harboring tumors with higher expression of DDR2 (p < 0.001). In this relatively large cohort of women with HSGOC, higher DDR2 expression was associated with lower miR-182 levels and worse PFS, suggesting that these molecules may be associated with mechanisms of HGSOC progression.Entities:
Keywords: Epithelial ovarian cancer; biomarkers; drug resistance; prognosis; survival
Mesh:
Substances:
Year: 2019 PMID: 30810094 DOI: 10.1177/1010428318823988
Source DB: PubMed Journal: Tumour Biol ISSN: 1010-4283